Gamma delta T-cell receptor (Vgamma9Vdelta2 subtype) (Vγ9Vδ2 TCR)

The Gamma delta T-cell receptor (Vγ9Vδ2 TCR) is a specialized immune receptor primarily found on the Vγ9Vδ2 subset of T cells, which constitute the majority of γδ T cells in human peripheral blood (Nature Reviews Immunology, 2013). This receptor is unique because it recognizes non-peptide phosphoantigens (PAgs), such as isopentenyl pyrophosphate (IPP) and (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP), in a Major Histocompatibility Complex (MHC)-independent manner (Science, 2020). The recognition mechanism requires the presence of butyrophilin proteins, specifically BTN3A1 and BTN2A1, which act as molecular sensors that signal the presence of intracellular PAgs to the TCR (Nature, 2020). In cancer, the dysregulation of the mevalonate pathway leads to the accumulation of IPP, making tumor cells susceptible to Vγ9Vδ2 T-cell-mediated lysis. Therapeutic interventions targeting this receptor include aminobisphosphonates like Zoledronic acid, which indirectly activate the TCR by increasing IPP levels, and novel bispecific antibodies (e.g., LAVA-1207) or monoclonal antibodies (e.g., ICT01) that directly engage the TCR or its butyrophilin ligands (Journal of Immunotherapy of Cancer, 2021). These strategies aim to harness the potent cytotoxic and pro-inflammatory capabilities of γδ T cells for treating both solid and hematological malignancies.

Other names

Vg9Vd2 TCRGamma-delta T-cell antigen receptorVgamma9Vdelta2 T-cell receptorPhosphoantigen-reactive TCR

Agonism of the TCR via phosphoantigen accumulation, direct TCR engagement by bispecific antibodies, or stabilization of butyrophilin-TCR complexes.